A COMMERCIAL STAGE BIOTECH COMPANY DEVELOPING AND SELLING PROPRIETARY COMPOUNDS TO TREAT ORPHAN AND RARE DISEASES
LOBE SCIENCE is a commercial stage drug development biotechnology company focused on selling and developing medicine to benefit patients of all ages.
With our acquisition of Altemia and Company we will commercialize a Medical Food named Altemia for the treatment of Sickle Cell Disease (SCD) in North America. We will engage with the very well-defined community of SCD clinics that treat the 100,000 patients in the United States. We have partnered with a European based Specialty Pharmaceutical Company for distribution in Europe and the Middle East.
We are also engaged in research and development using proprietary and patent pending derivatives of psychedelic compounds delivered in a way that will not induce a psychedelic trip. We call our patent pending compounds L-130 and L-131
We believe that treating patients in their HOME with easily administered, transformational medicines is the appropriate path to creating a global pharmaceutical marketplace that benefits all patients and allows them to be cared for by their personal physician.
Our team of biotech executives, collectively, have managed the development and regulatory approval of revolutionary drugs around the globe.
Our team of biotech executives, collectively, have managed the development and regulatory approval of revolutionary drugs around the globe.
Our Vision
To develop and deliver transformative therapeutic solutions to treat and potentially cure selected Orphan Diseases. Initially focusing on Chronic Cluster Headaches, a confidential pediatric Orphan Disease and Sickle Cell Disease.